GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascelia Pharma AB (FRA:7ZA) » Definitions » Institutional Ownership

Ascelia Pharma AB (FRA:7ZA) Institutional Ownership : 1.29% (As of Apr. 24, 2025)


View and export this data going back to 2020. Start your Free Trial

What is Ascelia Pharma AB Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Ascelia Pharma AB's institutional ownership is 1.29%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Ascelia Pharma AB's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Ascelia Pharma AB's Float Percentage Of Total Shares Outstanding is 0.00%.


Ascelia Pharma AB Institutional Ownership Historical Data

The historical data trend for Ascelia Pharma AB's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascelia Pharma AB Institutional Ownership Chart

Ascelia Pharma AB Historical Data

The historical data trend for Ascelia Pharma AB can be seen below:

2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31
Institutional Ownership 1.07 1.07 1.07 1.23 1.22 1.24 1.94 1.28 1.29 1.29

Ascelia Pharma AB Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Ascelia Pharma AB Business Description

Traded in Other Exchanges
Address
Hyllie Boulevard 34, Malmo, SWE, SE-215 32
Ascelia Pharma AB is an oncology-dedicated drug development company located in Malmo Sweden focused on orphan oncology It develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway The company has two drug candidates Orviglance and Oncoral in clinical development.

Ascelia Pharma AB Headlines

No Headlines